DCK and neoplasm: Genetic mutations of DCK are not a common mechanism of resistance to intrinsic or acquired resistance to gemcitabine, and DCK mutations in patients with pancreatic cancer is actually uncommon, present in less than 5% of all tumours analysed [30, 34], but our finding, if validated, may prevent this group of patients from receiving a potentially ineffective treatment.